- Home
- CLH vs GMAB Comparison
CLH vs GMAB Comparison
Compare CLH & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLH
- GMAB
- Stock Information
- Founded
- CLH 1980
- GMAB 1999
- Country
- CLH United States
- GMAB Denmark
- Employees
- CLH N/A
- GMAB N/A
- Industry
- CLH Environmental Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CLH Industrials
- GMAB Health Care
- Exchange
- CLH Nasdaq
- GMAB Nasdaq
- Market Cap
- CLH 13.9B
- GMAB 15.0B
- IPO Year
- CLH 1987
- GMAB N/A
- Fundamental
- Price
- CLH $250.02
- GMAB $20.47
- Analyst Decision
- CLH Strong Buy
- GMAB Buy
- Analyst Count
- CLH 9
- GMAB 8
- Target Price
- CLH $258.11
- GMAB $43.00
- AVG Volume (30 Days)
- CLH 399.4K
- GMAB 1.5M
- Earning Date
- CLH 10-30-2024
- GMAB 11-06-2024
- Dividend Yield
- CLH N/A
- GMAB N/A
- EPS Growth
- CLH 15.34
- GMAB 14.35
- EPS
- CLH 7.68
- GMAB 10.80
- Revenue
- CLH $5,797,005,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- CLH $10.09
- GMAB $30.31
- Revenue Next Year
- CLH $6.01
- GMAB $16.49
- P/E Ratio
- CLH $32.59
- GMAB $18.39
- Revenue Growth
- CLH 8.37
- GMAB 17.75
- 52 Week Low
- CLH $158.42
- GMAB $20.34
- 52 Week High
- CLH $267.11
- GMAB $32.88
- Technical
- Relative Strength Index (RSI)
- CLH 49.55
- GMAB 25.67
- Support Level
- CLH $240.00
- GMAB $20.50
- Resistance Level
- CLH $265.72
- GMAB $23.47
- Average True Range (ATR)
- CLH 6.02
- GMAB 0.46
- MACD
- CLH -0.78
- GMAB -0.16
- Stochastic Oscillator
- CLH 50.60
- GMAB 4.15
About CLH Clean Harbors Inc.
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.